uterine cervical neoplasms
Conditions
Interventions
A: chemotherapy:Paclitaxel/Cisplatin
B: chemotherapy:Paclitaxel/Carboplatin
Sponsors
Japan Clinical Oncology Group(JCOG)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) histologically proven uterine cervical cancer 2) squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the uterine cervix 3) one of the followings, 1.primary stage IVb cervical cancer 2.the first relapse or persistent cervical cancer after curative first line treatments 3.the second relapse or persistent cervical cancer after curative second line treatmets including radiation, systemic chemotherapy, hormonal therapy, or vaccination therapy for the first relapse 4) Patients may have been previously treated with less than 50 Gy of palliative radiation therapy 5) Patients have received no prior treatment or a certain interval must have elapsed from the last administration of previous treatments including palliative radiatinon therapy 6) one of the followings, 1.There is at least one metastatic lesion outside the pelvic cavity except paraaortic LN and/or inguinal LN 2.There is no metastatic lesion outside the pelvic cavity except paraaortic LN and/or inguinal LN and some of the lesions have been irradiated 3.All lesions are localized inside the pelvic cavity, and some of them have been irradiated 7) no prior surgical therapy for metastatic lesions of the lung or inside the pelvic cavity 8) no bilateral hydronephrosis 9) no prior chemotherapy including more than two platinium-containing regimens 10) no prior chemotherapy including taxane 11) age: 20 to75 years 12) PS: 0-2 13) ANC >=1,500 /mm3, Plt>=10.0 X 104/mm3, T-bil=50ml/min in using the Cockcroft-Gault equation, and normal ECG 14) written informed consent
Exclusion criteria
Exclusion criteria: 1) patients who have some neurologically functional disorder 2) symptomatic CNS metastasis 3) hypersensitive to alcohol 4) active infection 5) HBs antigen positive 6) uncontrollable hypertension 7) history of myocardiac infarction within six months 8) unstable angina 9) uncontrollable diabetes 10) Patients with a concomitant or prior invasive malignancy (except intramucosal malignancy which are curable with local therapy) who have had any evidence of the disease within the last 5 years 11) women during pregnancy or breast-feeding 12) patients with psychiatric liiness 13) patients who have been treated with the systemic steroids medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival, response rate, adverse events, severe adverse events, proportion of periods of non-hospitalization to those of the planned treatment | — |
Countries
Japan
Contacts
Public ContactRyo Kitagawa
JCOG0505 Coordinating Office Kanto Medical Center, NTT EC
Outcome results
None listed